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Abstract
This review examines the use of transporter knockout (KO) animals to evaluate transporter function at the choroid
plexus (the blood-CSF barrier; BCSFB). Compared to the blood-brain barrier, there have been few such studies on
choroid plexus (CP) function. These have primarily focused on Pept2 (an oligopeptide transporter), ATP-binding
cassette (ABC) transporters, Oat3 (an organic anion transporter), Svct2 (an ascorbic acid transporter), transthyretin,
ion transporters, and ion and water channels. This review focuses on the knowledge gained from such studies,
both with respect to specific transporters and in general to the role of the CP and its impact on brain parenchyma.
It also discusses the pros and cons of using KO animals in such studies and the technical approaches that can be
used.
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Introduction
Choroid plexus (CP) epithelial cells and their linking tight
junctions form the blood-CSF barrier (along with the ara-
chnoid membrane) and are the primary site of CSF secre-
tion. As with the cerebral endothelium, the site of the
blood-brain barrier (BBB), the CP epithelium possesses a
wide variety of transporters [1-4]. CP transporters are
involved in cell and CSF homeostasis, the movement of
nutrients into and waste products out of the CSF, and CSF
secretion. In addition, as ependymal cells are not linked by
tight junctions, CP transport may impact periventricular
brain regions and potentially deeper structures by affecting
CSF composition.
It is important to identify which transporters are present
at the CP and their role (physiological and potentially
therapeutic). However, the latter is complicated by the
array of transporters present, overlapping substrate specifi-
city and often a lack of specific inhibitors. One approach
that has proven useful in transporter studies is the use of
animals with gene deletions (e.g. KO mice) or gene muta-
tions (functional knockouts). This approach has been used
extensively in BBB studies to examine the role of different
ATP-binding cassette (ABC) transporters in drug efflux
(e.g. [5-8]). Multidrug resistance protein [MDR], breast
cancer related protein [BCRP] and multidrug resistance
associated proteins [MRPs] are all present at the BBB and
have considerable substrate overlap. In comparison, rela-
tively few CP transport studies have employed KO ani-
mals. This paper reviews those studies and the insights
they give on CP transport and the relative functions of the
blood-CSF and the blood brain barriers. It also discusses
some methodological considerations when performing
such studies. This paper does not aim to review the pro-
duction of KO (and transgenic) mice.
Studies of CP and blood-CSF barrier transport using KO
animals
Multiple transporter KO mice have been generated. For
example, there have been BBB transport studies on KO
mice for Abcb1 (P-glycoprotein; Mdr1; [7]), Abcg2 (breast
cancer related protein; Bcrp; [9]), Abcc-1 and -4 (multi-
drug resistance associated protein-1 and -4; Mrp-1 and -4;
[10,11]), Oat3 and Oatp1a4 (two organic anion transpor-
ters; [11,12]) and Mct8 (a monocarboxylic acid transpor-
ter; [13]). Blood-brain barrier transport studies have also
been performed on mice with naturally occurring muta-
tions that result in transport inactivation (e.g. Octn2, an
organic cation transporter, and Obr, a leptin transporter;
[14,15]). Many more mouse KOs have been developed and
used in transporter studies in non-brain tissues (e.g. kid-
ney). As well as mice, there are also some naturally occur-
ring functional knockouts in other species that have been
used for BBB studies. Thus, there are Mrp2 KO rats (Eisai
hyperbilirubinemic rat, [16]) and an Mdr1 KO in collie
dogs [6] allowing species comparisons on the role of speci-
fic transporters. Currently, a number of transporter KO
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rats are under development, with the Mrp1 KO now being
commercially available (SAGE Labs, St. Louis, MO, USA).
In contrast, the effect of transporter KO on CP has been
the subject of far fewer studies and these are reviewed
below. They provide insight into the types of CP experi-
ments that can be performed, and their limitations, as well
as information on the function of particular CP transpor-
ters. Broadly, the effects of gene deletion on transport has
been mostly assessed in vitro using isolated CP, with lim-
ited studies on CP epithelial cell cultures because of the
large number of mice required. In vitro studies have the
advantage of enabling CP study without impact from
other tissues (e.g. BBB, brain parenchyma). In vivo, most
investigations have looked at CP transport and CSF entry
after intravenous administration of compounds. Very few
have used intracerebroventricular (icv) administration to
study the effects of gene deletion on clearance from CSF.
The impact of the transporter KOs in relation to CP
function is described in the sections below. Figure 1 gives
the location of the different transporters at the CP.
Oligopeptide transport (Pept2)
Pept2 (SLC15a2) is a member of the proton-coupled oligo-
peptide transporter (POT) family which also includes
Pept1, and two proton-coupled histidine transporters
(Pht1, Pht2) [17,18]. All of these POTs transport small oli-
gopeptides (2-3 amino acids) and peptidomimetics (e.g.
alpha amino acid containing beta-lactam antibiotics), but
only Pht1 and Pht2 can transport an amino acid, histidine
[18]. Pept2 is present in a number of tissues including kid-
ney, where it is involved in peptide reabsorption [19]. In
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Figure 1 Schematic of the CP with the distribution of the transporters discussed in this paper [1,39,42]. For Aqp1, the distribution is
primarily apical (CSF-facing) but some has been described on the basolateral membrane [1]. An apical and subapical distribution of Mdr1 has
been reported [38]. However, it should be noted that the levels of Mdr1 at the CP are much lower than that found at the BBB.
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brain it is present in the apical membrane of the CP
epithelium but it is also present in neurons (neonate and
adult) and astrocytes (neonate but not adult) [20]. It is not
present at the BBB [20]. While both Pht1 and Pht2 are
present in brain and CP, Pept1 is not [17,18,21,22]. Pht1 is
present in neurons and small non-neuronal cells [22], but
it is not known which brain parenchymal cells express
Pht2.
To examine the functional importance of CP Pept2, we
developed a Pept2 KO mouse (Pept2-/-) [23]. These mice
are normal in appearance and body weight. We initially
examined the uptake of glycylsarcosine (GlySar) into iso-
lated choroid plexus [23]. GlySar is a hydrolysis resistant
dipeptide that is a POT substrate. In the CPs from the
Pept2-/- mice [14C]GlySar uptake was reduced by ~90%
compared to wild-type Pept2+/+ animals [23,24] and we
have since found similar major reductions for carnosine,
another di-peptide, as well as for cefadroxil and 5-amino-
levulinic acid (5-ALA), two peptidomimetics ([24-26];
Figure 2). In the case of cefadroxil there was evidence for
a small component of uptake (10-15%) due to an organic
anion transporter [25]. These results indicate that Pept2 is
the predominant uptake transporter for di- and tri-pep-
tides and small peptidomimetics in the isolated CP, a
result further confirmed by the fact that L-histidine, a
Pht1 and Pht2 substrate, did not alter uptake of these
substrates.
The Pept2-/- mouse has also allowed examination of the
role of Pept2 in the distribution of potential substrates
between blood, CP, CSF and brain in vivo. The first
experiments examined GlySar, carnosine, cefadroxil and
5-ALA distribution after iv administration [27-30]. These
experiments showed a marked increase in CSF uptake in
the Pept2-/- mice (Figure 3) as the transporter functions to
clear substrates from the CSF into CP [18]. Interestingly,
the effect of Pept2 on uptake into cerebral cortex was
much smaller and more complex (Figure 3; see BBB vs.
BCSFB discussion below). These experiments also served
to emphasize one point about the use of transporter KO
mice to study CP transport; that is, unless the transporter
is expressed only in CP (or unless a tissue specific KO is
used), there may be alterations in plasma substrate con-
centrations between the null and wild-type which necessi-
tate referencing tissue concentrations to the plasma
concentration. Even though kidney Pept2 caused wild-type
mice to have higher plasma concentrations of Pept2 sub-
strates after iv injection (e.g. [29]), these concentration
changes did not account for the differences in CSF and CP
concentrations between the two genotypes.
The Pept2-/- mouse has also been used to look at sub-
strate distribution after intracerebroventricular (icv)
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Figure 2 The uptake of [14C]GlySar, [3H]cefadroxil, [3H]
carnosine and [14C]5-ALA was measured in isolated CP from
Pept2-/- (KO) and Pept2+/+ (WT) mice [24-26]. The KO uptake is
expressed as a % of WT. With the exception of cefadroxil (where a
small portion of uptake is mediated by an organic anion
transporter), uptake in CPs from KO mice was < 10% of WT.
Figure 3 The uptake of [14C]GlySar, [3H]cefadroxil, [3H]
carnosine and [14C]5-ALA into CSF and cortex after intravenous
administration into Pept2-/- (KO) and Pept2+/+ (WT) mice
[27-30]. For both genotypes, CSF/plasma and cortex/plasma ratios
were calculated to account for differences in plasma concentrations
which were lower in the KO mice because of reduced renal
reabsorption of these peptides/peptidomimetics. The KO ratios were
then expressed as a % of WT. Note the marked increase in CSF
uptake for all 4 substrates in the KO while the effect on cortex was
more modest (GlySar, cefadroxil), absent (5-ALA) or even reversed
(carnosine).
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administration. These studies have shown that the clear-
ance of GlySar, cefadroxil and L-kyotorphin (an endogen-
ous analgesic dipeptide) from CSF is reduced in Pept2-/-
mice compared to wild-type mice and that this effect is
matched by reduced CP uptake in the null mice [31,32]
(Figure 4). Using autoradiography, we studied the impact
of Pept2 deletion on penetration of [14C]GlySar into peri-
ventricular brain in adult mice. These studies are compli-
cated by the presence of Pept2 in some neurons but did
show that there is a rapid drop-off in GlySar (MW = 146)
concentration with distance from the CSF system [32]
The Pept2-/- mice show no obvious phenotypic differ-
ences from the Pept2+/+ mice under normal conditions
(e.g. in growth or behavior). However, we have found that
the null mice are more susceptible to 5-ALA-induced neu-
rotoxicity after systemic administration (as might be
expected from the higher 5-ALA CSF concentrations
[27]). Intracerebroventricular administration of L-kyotor-
phin also induces more analgesia in the null mice, as
might be expected from the reduced clearance of this drug
from CSF into CP [31].
ATP-binding cassette (ABC) transporters
The ABC transporters have been studied extensively at the
BBB using KO mice and these transporters markedly
reduce the penetration of a wide variety of drugs from
blood to brain. Thus, as shown by Schinkel and colleagues,
deletion of P-glycoprotein markedly increases the entry of
a wide variety of drugs into brain [7,33]. Similarly, Bcrp
KO can significantly impact the brain uptake of specific
drugs [9]. For Mrp-1 and -4 KOs there are some more
modest effects [10,11]. It should be noted that under nor-
mal housing and dietary conditions, Mdr1, Bcrp, Mrp1
and Mrp4 KO mice are normal in appearance, body
weight and fertility [7,34-36].
Data from KO animals, supported by immunohisto-
chemistry, have shown that CP epithelial cells differ from
cerebral capillary endothelial cells in the distribution of
ABC transporters and, therefore, the effects of transpor-
ter KO. Thus, Shen et al. [37] found that while Mdr1a/b
KO caused increased penetration of topcotecan into
brain parenchyma, it causes reduced penetration into
ventricular CSF [37]. They also found that Bcrp KO mice
had increased penetration of the drug into brain parench-
yma but reduced penetration into CSF. The effects of
Mdr1a/b and Bcrp deletion were additive at both sites.
These differential effects of the KOs on drug entry at the
blood-CSF and blood-brain barriers are due to the two
ABC transporters being on the CSF-facing membrane at
the CP and at the blood-facing membrane at the cerebral
endothelium [37-39].
In contrast to the Shen et al. [37] study, Doran et al.
[40] found marked increases in the brain and CSF entry
of metoclopramide, risperidone and 9-OH-risperidone in
Mdr1a/b KO mice compared to WT, although the effects
on CSF were less than on brain. A potential reason for
the difference may be the site of CSF sampling. Whereas
Shen et al. [37] sampled ventricular CSF adjacent to the
CP by microdialysis, Doran et al. [40] sampled bulk CSF
from the cisterna magna where there may have been
more BBB influence as the CSF flows past brain tissue.
Interestingly, Mealey et al. [6] examined brain and CSF
penetration of 99 mTc-sestamibi, a Mdr1 substrate, in
WT dogs and dogs with a mutation in Mdr1 and found
that while brain levels were elevated with the mutation,
CSF levels were unchanged. In this study, CSF was
sampled from the cisterna magna which may have influ-
enced the results.
It should be noted that the relative impact of Mdr1 at
the BBB and BCSFB depends upon not only cellular
localization but also the amount of the transporter.
Thus, the amount of Mdr1 at rat and human CP is
much less than that found in cerebral microvessels, as
assessed by Western blot [41]. This is in marked con-
trast to another ABC transporter, Mrp4, where the
expression is much higher in CP than at the BBB [41].
In contrast to Mdr1 and Bcrp, Mrp4 is thought to be
on the basolateral membrane of the CP epithelium and
the luminal membrane of the cerebral endothelium, i.e.
the transporter at the two sites may work in concert to
keep CNS levels low [39]. Thus, Leggas et al. [35] found
that Mrp4-deficient mice had much greater entry of an
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Figure 4 Comparison of the carrier-mediated clearance of [14C]
GlySar, [3H]cefadroxil, L-[3H]kyotorphin (L-KTP) from CSF after
intracerebroventricular administration to Pept2-/- (KO) and
Pept2+/+ (WT) mice [31,32]. A half-life for the clearance of these
compounds (corrected for diffusion using radiolabeled mannitol)
was calculated and the KO values expressed as a % of WT. Note the
prolonged half-life for each of the compounds in the KO mice
reflecting reduced CP-mediated clearance.
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anti-cancer agent, topotecan, into CSF and brain than
WT mice.
Mrp1 is on the basolateral membrane of the CP epithe-
lium involved in clearing substrates from the CP to blood
[39,42]. Thus, Wijnholds et al. [43] found that CSF levels
of etoposide were increased 10-fold by Mrp1 KO. How-
ever, Lee et al. [16] found no difference in the efflux of
estradiol-17b-glucuronide and 2,4,-dinitrophenyl-S-glu-
tathione from CSF. This may reflect the relative impor-
tance of Mrp1 for these compounds compared to other
efflux mechanisms. Lee et al. [16] also examined the
transport of estradiol-17b-glucuronide and 2,4,-dinitro-
phenyl-S-glutathione in the Mrp2 deficient Eisai rat and
found no effect on clearance from the CSF. This may be
due to the very low or negligible expression of Mrp2 at
the CP epithelium [16].
Organic anion transport
There are multiple organic anion transporters at the
blood-CSF and blood-brain barriers, including (but not
limited to) members of the SLC22 (Oat) and SLC21/
SLCO (Oatp) families [42,44]. These transporters have
overlapping substrate affinities making it difficult to assign
the relative role of individual transporters. Sweet et al.
[45,46] developed an Oat3 KO mouse to examine the role
of this transporter. The null mice are normal in appear-
ance and are fertile [45]. Oat3 is present on the apical
membrane of the CP epithelium (Figure 1) where it is
involved in clearing organic anions from CSF. In isolated
CP, para-aminohippuric acid and fluorescein uptake was
essentially abolished in Oat3 null mice, whereas the uptake
of estrone sulfate was only reduced by a third and tauro-
cholate uptake was unaffected [45,46]. Thus, the impor-
tance of Oat3-mediated transport at the CP depends on
the nature of the organic anion. In addition, it is still
uncertain as to the importance of blood-CSF vs. blood-
brain barrier organic anion transport as the Oat3 KO
mouse has not been used for in vivo CP studies.
Transthyretin (TTR)
TTR is the protein most abundantly synthesized and
secreted by the CP. TTR binds thyroxine (T4) and retinol
and it has been hypothesized that TTR is involved in the
transport of T4 from blood to brain. Palha et al. [47,48]
examined this hypothesis in TTR null mice. They found
no difference in the rate of [125I]T4 entry into the brain in
TTR-null mice. They also found that cortex, cerebellum
and hippocampus T4 levels were similar in the TTR-null
and WT mice. However, CP T4 levels were very markedly
lower in null mice (14% of WT). Thus, TTR effects on T4
are probably limited to the CP-CSF system and areas adja-
cent to that system. Interestingly, Richardson et al. [49]
found that apoptosis in neural stem cells/progenitor cells
in the subventricular zone was reduced in TTR null mice
to a similar extent to that found in hypothyroid mice.
Sodium-dependent vitamin C transporter-2
Ascorbic acid is not synthesized in the brain and is, there-
fore, reliant on transport from blood [50]. The sodium-
dependent vitamin C transporter-2 (svct2; slc23a1) is
highly expressed at the CP [51] where it is present at the
basolateral membrane transporting ascorbic acid from
blood to CP (Figure 1) [52]. Svct2 appears to be essential
for this transport as Svct2 KO mice have undetectable
ascorbic acid levels in the brain at birth and die perinatally
[53]. As Svct2 is highly expressed at the CP but absent
from the BBB [50] this suggests that the very low brain
ascorbic acid levels in the KO are due to the lack of the
CP transporter.
Folate transport
Some of the complexity of using transporter KO mice to
study CP function is demonstrated by folate transport.
Folate transport from blood to CSF at the CP is thought
to involve Folate Receptor alpha (FRa) at the basolateral
membrane and the Reduced Folate Carrier 1 (Rfc1) at the
apical membrane [50]. KO mice have been produced for
both FRa and Rfc1 but both are embryonic lethal with the
embryos showing severe abnormalities [54,55]. Even
though there is some embryo rescue by giving pregnant
dams folic acid, RFC null neonates are markedly growth
retarded and have multiple compromised organ systems
[55]. The absence of adult KO animals make transport
studies difficult while the effects on multiple organ sys-
tems make it difficult to assess whether any effects on
brain are direct or indirect. Analysis of folate transport at
the CP would be greatly facilitated by the generation of
CP-specific KO mice.
Ion transporters/channels
The CP has a wide array of ion transporters and channels
[1] that are involved in CSF and cellular ion homeostasis,
some of which have been examined using KO mice (the
Na+/H+ exchanger, Nhe1; the Na/bicarbonate cotranspor-
ters, Nbcn1 and Nbcn2; Figure 1). Changes in the CSF
composition of a number of ions would affect neuronal
excitability. Thus, the CSF composition of potassium and
calcium are regulated very tightly during changes in
plasma composition [56,57]. Similarly, CSF pH is also sub-
stantially regulated during changes in blood pH (with the
exception of acute respiratory changes). The CPs are also
the primary site of CSF secretion which involves CP ion
transporters and channels [1]. Understanding which trans-
porters are involved in CSF secretion may generate targets
to treat raised intracranial pressure and hydrocephalus
and KOs have been used to try and define the roles of spe-
cific transporters. It should be noted that the transporters
present at the CP are not tissue specific. Many ion trans-
porter KOs result in significant developmental effects on
the animals. For example, in relation to the KOs described
below, Nhe1 KO mice have ataxia, seizures and growth
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retardation [58,59], Nbcn1 KO mice develop blindness and
auditory problems [60] and Nbcn2 KO mice mostly die
around weaning unless special care is taken with feeding
[61]. With such profound effects, it is often possible that
there are secondary and compensatory effects of the trans-
porter deletion.
Two Na/bicarbonate cotransporters (Nbc), Nbcn1 and
Nbcn2 are present at the CP basolateral membrane [62].
Targeted deletion of Nbcn2 (Slc4a10) resulted in reduced
ventricular size, that probably results from reduced CSF
production [61]. In addition, the CP epithelial cells from
these KO mice also have altered pH handling, although
there are some compensatory changes in the Na+/H+
exchanger, Nhe1 [63].
Nhe1 is normally located on the CP apical membrane
where it is involved in H+ excretion [1]. In Nhe1 KO mice,
acid extrusion (in the absence of CO2/HCO3
-) from the
CP was almost completely abolished, demonstrating the
importance of this transporter (rather than other Nhe iso-
forms) in epithelial cell pH regulation [63]. Interestingly,
Nhe1 KO did not change the expression of Nbcn1 or
Nbcn2 in the CP [63].
Speake et al. [64] have used patch clamp to examine CP
from mice deficient in a chloride channel, Clc2. They
found that the loss of this channel did not alter the
inward-rectifying anion conductance in CP epithelial cells,
a conductance thought to be important in CSF secretion.
Aquaporins
A water channel, aquaporin 1 (Aqp1), is highly expressed
at the apical membrane of the CP epithelium (Figure 1).
Aqp1 null mice appear normal apart from a mild growth
retardation but they are unable to create a hypertonic
urine during water deprivation [65]. Oshio et al. [66] com-
pared the water permeability of choroid plexus from Aqp1
null and wild-type mice and found a five-fold reduction in
the former. Aqp1 null mice also had reduced CSF produc-
tion (~25%) and intracranial pressure. There are currently
no specific inhibitors for aquaporins and, therefore, knock-
out mice are an important method for elucidating their
function.
Methodological considerations
As noted above, almost all (if not all) transporters are
expressed in more than one cell type. Thus, care must be
taken in designing experiments and interpreting results
from KO animals (e.g. a transporter KO may affect blood
levels of a substrate as well as CP transport). This is parti-
cularly the case when assessing a non-transporter pheno-
type (such as behavior or neurotoxicity). A method of
limiting such concerns is to use cell-specific KO mice
[67,68], but these have not, as yet, been used for CP trans-
porter studies.
Another concern is potential compensation for a trans-
porter KO. As there can be considerable substrate
overlap between different transporters, it is possible that
the loss of one transporter may be compensated for by
the upregulation of another. We have examined this pos-
sibility in the Pept2-/- mouse and found no mRNA or
functional upregulation of the other POT family mem-
bers at the CP [29] but this may not be the case for other
transporters. Thus, deletion of the Na/bicarbonate trans-
porter, Nbcn2, alters the CP location of the Na+/H+
exchanger, Nhe1, a transporter that is also involved in
pH regulation [63]. One potential method for alleviating
this problem is to use conditional KOs where the gene of
interest can be knocked out at a specific time in the ani-
mal’s life, lessening the chance of adaptive changes that
might occur during development [67,68]. Such temporal
conditional KO mice have, as yet, not been used in CP
transporter studies.
Another approach to lessen potential compensatory
effects of knocking out a gene is to acutely knock down
gene expression with a small interfering RNA (siRNA).
This approach is easier in vitro than in vivo (siRNA deliv-
ery). It has been used by both Wang et al. [69] to knock
down the expression of the divalent metal transport 1
(Dmt1) in a choroid plexus epithelial cell line and by
Boassa et al. [70] to knock down aquaporin 1 in primary
choroid plexus epithelial cell cultures.
BBB vs. BCSFB
The importance of CP transport to brain parenchyma has
long been debated. For D-glucose, the high rate of trans-
port by BBB Glut-1 and the proximity of the vasculature
to neurons results in CP D-glucose transport having a
very minor role in the uptake of this essential nutrient
into brain. In contrast, for ascorbic acid, CP transport (via
the sodium dependent vitamin C transporter, Svct2) plays
a predominant role with brains of Svct2 KO mice having
almost no ascorbic acid [50]. The role the CP plays in the
transport of nutrients, waste products or pharmaceuticals
will depend on the transporters present at the BCSFB,
BBB and parenchymal cells, the passive diffusion of those
compounds across the barriers and the relative distance of
the parenchymal cells to the ventricular system. KO ani-
mals give a methodology to examine the role of CP trans-
port, although care is needed in interpreting the data
based on the location of the deleted transporter (CP alone,
CP+BBB, CP +parenchymal cells), the size of the brain
(which will effect penetration from the CSF into parench-
yma) and the target site (periventricular vs. distant from
ventricular system) as outlined below.
We have examined the effect of Pept2 KO on cerebral
cortex penetration of GlySar, cefadroxil, carnosine and 5-
ALA after intravenous administration. While the accu-
mulation of these drugs in CSF is markedly increased
(300-900%; Figure 3), the effects on cerebral cortex were
more modest or even the reverse to that found in CSF
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(Figure 3). We examined these findings further using icv
injections of [14C]GlySar and autoradiography [32]. Even
though GlySar has a molecular weight of 146 and epen-
dymal cells are not linked by tight junctions, there was a
rapid decline in tissue [14C]GlySar levels with distance
from the ependyma in both Pept2-/- and WT mice with
concentrations dropping by 50% over 0.53 and 0.34 mm,
respectively. Thus, the impact of changes in CSF concen-
trations resulting from a loss of a CP transporter was
likely to be limited to the periventricular zone. Milhorat
et al. [71] examined the penetration of radioactive
sodium from the CSF system into brain in rhesus mon-
key after an intravenous infusion and they also found a
steep decline in concentration as tissue was sampled
further away from the ependymal and subarachnoid
space.
It should be noted that in our studies on the effects of
Pept2 KO on the distribution of peptides into CSF and
brain parenchyma, described above, we examined the
impact after a single injection (iv or icv) to mimic drug
administration. The effects of CP transporter KO on brain
parencyhma may be greater for compounds normally
found in the body. Thus, as noted above, Svct2 KO mice
have very low brain vitamin C levels [53] that is attributa-
ble to the loss of blood to CSF transport at the CP. With a
naturally-occurring compound there may be chronic
changes in CSF levels in the transporter KO with a greater
impact on brain parenchyma.
Some of the potential difficulties in using whole animal
KO animals to assess the effects of CP transport on brain
parenchyma are exemplified by the effects of such KOs for
the ABC transporters. Mrp4 is present at the CP and the
BBB and in both tissues it is involved in transporting sub-
strates back to blood [39,42] making it difficult to attribute
effects on CSF and brain parenchyma to one barrier site
alone. Mdr1 and Bcrp are also present at both the CP and
BBB, but they are on the CSF (brain)-facing membrane at
the CP and the blood-facing membrane at the BBB [39].
This should give an opportunity to examine the impact of
the two sites of transport which have opposing effects.
However, care is necessary as the balance will be inti-
mately related to sampling sites, i.e. parenchymal distance
from the CSF system and the distance of the CSF sampling
site from the CPs.
In general, the extent of the impact of a CP transporter
knockout on the parenchyma (and periventricular zone in
particular) will depend upon multiple variables. It will
depend upon the magnitude of the KO effect on substrate
CSF levels, the clearance via CSF flow, the rate of penetra-
tion into parenchyma across the ependymal, trapping or
exclusion of the substrate from parenchymal cells, and the
rate of diffusion and/or transport across the BBB. Com-
pensatory transporters (in the absence or presence of
upregulation) will also serve to confound this issue.
Conclusions
Transporter KO animals are a useful tool in elucidating
the functional role of CP transporters. This is particularly
the case as we gain more understanding of the overlapping
substrate specificities of different transporters and the pos-
sible effects of inhibitors on multiple transport systems. As
yet, only the effects of whole animal transporter knockouts
on CP transport have been examined. Under normal con-
ditions the transporter KOs examined had no obvious
phenotype associated with the CP transporter deletion,
with the exception of Svct2. However, such deletions can
have marked effects on the CSF levels of substrates, drug
efficacy and substrate-induced neurotoxicity. The effects
of CP transporter KOs on brain parenchyma substrate
delivery are variable with the greatest effects on the peri-
ventricular zone rather than the deep brain structures.
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